【摘要】：目的觀察兩種不同霧化吸入方式吸入硫酸特布他林和布地奈德聯(lián)合多索茶堿治療變異性哮喘患兒的臨床療效及安全性。方法將78例變異性哮喘患兒隨機(jī)分為對(duì)照組39例與試驗(yàn)組39例。2組均給予常規(guī)治療及對(duì)癥治療。對(duì)照組采用超聲霧化吸入的方式,2組試驗(yàn)組采用空氣壓縮泵霧化吸入的方式,均給予硫酸特布他林霧化液2 mL+布地奈德混懸液2 mL+0.9%Na Cl 20 mL,每日2次。2組均給予多索茶堿5 mg·kg~(-1)+5%葡萄糖溶液50 mL,靜脈滴注,每日1次。2組患兒均治療5 d。比較2組患兒的臨床療效、外周血嗜酸粒細(xì)胞(EOS)、嗜酸性粒細(xì)胞陽離子蛋白(ECP)、免疫球蛋白E(IgE)、白細(xì)胞介素-4(IL-4)水平及藥物不良反應(yīng)發(fā)生情況。結(jié)果治療后,試驗(yàn)組總有效率為92.31%(36例/39例),對(duì)照組為74.36%(29例/39例,P0.05)。治療后,對(duì)照組和試驗(yàn)組外周血嗜酸粒細(xì)胞分別為(0.79±0.10)×10~9/L,(0.54±0.07)×10~9/L,IgE分別為(176.49±20.11),(107.49±14.44)U·mL~(-1),IL-4分別為(80.92±9.78),(50.98±6.44)ng·mL~(-1),差異均有統(tǒng)計(jì)學(xué)意義(均P0.05)。對(duì)照組和試驗(yàn)組第1秒用力呼氣容積分別為(0.64±0.10),(0.70±0.12)L,用力肺活量分別為(2.38±0.29),(3.38±0.37)L,第1秒用力呼氣容積占用力肺活量的比值分別為80.39±8.98,90.88±10.02,均顯著高于治療前,且試驗(yàn)組顯著高于對(duì)照組(P0.05)。2組的藥物不良反應(yīng)均為胃腸道不適和皮疹,試驗(yàn)組和對(duì)照組的藥物不良反應(yīng)發(fā)生率分別為5.13%(2例/39例),7.69%(3例/39例),差異無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論空氣壓縮泵霧化吸入方式聯(lián)合多索茶堿治療小兒變異性哮喘臨床療效顯著高于超聲霧化方式,安全性高。
[Abstract]:Objective to observe the efficacy and safety of inhaled terbutaline sulfate and budesonide combined with doxofylline in the treatment of children with variant asthma. Methods 78 children with variant asthma were randomly divided into control group (39 cases) and experimental group (39 cases). The control group was inhaled by ultrasonic atomization. All patients were given 2 mL budesonide suspension of 2 mL budesonide sulfate, 20 mL NaCl, 50 mL doxophylline 5 mg kg ~ (-1) 5% glucose solution twice a day for 5 days. The clinical efficacy, eosinophil (EOS), eosinophil cationic protein (ECP), immunoglobulin E (IgE), interleukin-4 (IL-4) levels and adverse drug reactions were compared between the two groups. Results after treatment, the total effective rate was 92.31% (36 / 39) in the trial group and 74.36% (29 / 39) in the control group (P0.05). After treatment, the eosinophils in peripheral blood of the control group and the experimental group were (0.79 鹵0.10) 脳 10 ~ (9) / L, (0.54 鹵0.07) 脳 10 ~ (9) L ~ (-1), (176.49 鹵20.11), (鹵14.44) U mL ~ (-1) IL-4, respectively (80.92 鹵9.78), (, 50.98 鹵6.44) ng mL ~ (-1), respectively (P 0.05). The forced expiratory volume was (0.64 鹵0.10), (鹵0.12) L, forced vital capacity was (2.38 鹵0.29), (鹵3.38 鹵0.37) L in the control group and the experimental group, respectively. The ratio of forced expiratory volume occupying capacity in the first second was 80.39 鹵8.98 鹵90.88 鹵10.02, which was significantly higher than that before treatment. The adverse drug reactions in the trial group were significantly higher than those in the control group (P0.05). The incidence of adverse drug reactions in the trial group and the control group was 5.13% (2 / 39 cases) and 7.69% (3 / 39 cases) respectively. The difference was not statistically significant (P0.05). Conclusion the clinical efficacy of aerosol inhalation with air compression pump combined with doxofylline in the treatment of children with variant asthma is significantly higher than that in ultrasonic atomization.
【作者單位】： 余姚市第二人民醫(yī)院兒科;
【基金】：浙江省衛(wèi)生適宜技術(shù)成果轉(zhuǎn)化計(jì)劃基金資助項(xiàng)目(2011ZHB012)
【分類號(hào)】：R725.6

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 朱少元;顧遠(yuǎn)平;;多索茶堿治療小兒毛細(xì)支氣管炎80例臨床觀察[J];大家健康(學(xué)術(shù)版);2011年09期

2 邱建輝;肖錦霞;;多索茶堿治療小兒毛細(xì)支氣管炎臨床觀察[J];中國實(shí)用醫(yī)藥;2012年17期

3 朱少元;顧遠(yuǎn)平;;多索茶堿治療小兒毛細(xì)支氣管炎臨床觀察[J];中國誤診學(xué)雜志;2012年02期

4 焦逢春;海春芳;;多索茶堿治療嬰幼兒毛細(xì)支氣管炎的療效觀察[J];中國醫(yī)藥指南;2013年11期

5 卓瑪措;肖延風(fēng);沙吉;;靜脈滴注多索茶堿輔治嬰幼兒急性肺炎療效分析[J];中國兒童保健雜志;2006年06期

6 孫云,高英,李樂,謝振華;多索茶堿靜脈應(yīng)用治療兒童哮喘危重狀態(tài)的療效分析[J];寧夏醫(yī)學(xué)雜志;2005年11期

7 付宏;陳其芬;黃昌洪;;多索茶堿佐治小兒毛細(xì)支氣管炎療效及安全性觀察[J];現(xiàn)代醫(yī)藥衛(wèi)生;2009年24期

8 趙小月;;多索茶堿治療嬰幼兒毛細(xì)支氣管炎52例療效觀察[J];長江大學(xué)學(xué)報(bào)(自科版);2013年24期

9 李維彬;;對(duì)小兒變異性哮喘39例的臨床體會(huì)[J];中國醫(yī)藥導(dǎo)報(bào);2007年09期

10 彭海平;朱慧芳;馬杰;;“三伏貼”治療兒童變異性哮喘27例[J];中國實(shí)用醫(yī)藥;2011年16期

相關(guān)會(huì)議論文 前1條

1 李德庚;何曉玲;汪葉紅;阮健;鄭伯強(qiáng);;兒童變異性哮喘肺功能的研究[A];中華醫(yī)學(xué)會(huì)第三次全國兒科基層醫(yī)師學(xué)術(shù)會(huì)議論文匯編[C];2007年

相關(guān)碩士學(xué)位論文 前1條

1 李婭寧;布地奈德聯(lián)合不同藥物霧化吸入治療兒童哮喘療效比較[D];青島大學(xué);2017年

，

本文編號(hào)：2132914